Cannabis: At the beginning of December, the National Health Surveillance Agency (Anivsa) approved yet another product based on the Cannabis plant (marijuana). The drug, called Cannabidiol Verdemed 23.75 mg/mL, is an oral solution made with the substance of the same name, and with up to 0.2% of tetrahydrocannabinol (THC), another by-product of Cannabis, but with psychoactive principles.
Authorized by Anvisa through Resolution RE 4.475, the new cannabinoid can be sold normally in pharmacies and drugstores in Brazil, upon medical prescription made in type B prescription (blue prescription). With this, the company will be able to import the product ready-to-use from Colombia, distributing and marketing it in the country.
What is cannabidiol for?
In Brazil, cannabidiol (CBD) is used in drugs authorized by Anvisa mainly for the treatment of muscle spasms related to multiple sclerosis (MS), a serious neurological, chronic and autoimmune disease. However, there are other CBD-based products marketed in other countries, indicated for the treatment of epilepsy, Parkinson’s or Alzheimer’s disease, or as analgesics in terminal cancer patients.
Anvisa’s standard for this category of cannabis-derived drugs determines that they are prescribed only in cases where other forms of treatment are not demonstrating the intended effect. The indication and form of use of cannabidiol are the prescribing physician’s responsibility.